Podcasts about Cardiology

On this episode of JHLT: The Podcast, the Digital Media Editors invite author Dr. Ayumi Goda, from the Kyorin University Hospital in Tokyo, Japan, to discuss her team's paper, “Prevalence of occult HFpEF and age-specific efficacy of passive leg raise in pulmonary hypertension.” The discussion explores: How clinical observations led to the idea for a study on whether the passive leg raise could unmask occult HFpEF The potential diagnostic value of the passive leg raise in differing patient populations Age-specific cutoffs that may influence what kind of testing to use in clinical practice For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Global issues that impact cardiovascular health include access to, and continuity of, care for migrant workers, as well as rising temperatures in both rural and urban environments. Nurse Practitioner and researcher Daniel Smith, PhD, AGPCNP-BC, CNE, FAAN, shares strategies to help improve cardiovascular disease prevention and management to help every patient everywhere have improved outcomes.Related resources:Global Cardiovascular Nursing Leadership Forum: gcnlf.netCE course: https://pcna.net/course/rural-and-environment-health-a-cross-roads/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Dr. Salim Virani as he explores global trends in cardiovascular disease, including shifting risk factors, emerging therapies, and prevention strategies. From disparities in care to the promise of primordial and even pre-primordial prevention, this conversation highlights what nurses and other healthcare professionals can do to improve heart health worldwide.Cleveland Clinic study on risk factors: https://pubmed.ncbi.nlm.nih.gov/35504796/ More information and resources can be found here: https://gcnlf.pcna.net/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken discuss the biggest news stories in the medical world, starting with a targeted itch-relief for the various types of bee/wasp/hornet stings, raising the question of what is in bee/hornet/wasp venom that causes pain, itching, as well as the more severe allergic reactions that can lead to anaphylaxis. Next up, new research linking prenatal exposure to acetaminophen (like in Tylenol) with Autism and ADHD and why some medical professionals are pushing back. Then, Doug and Dr. Ken continue the pain-reliever conversation and the benefits of routinely taking low-dose Aspirin, but the importance that a routine like this should be done under a doctor's supervision as there can be adverse effects if you are not someone that needs to be taking low-dose Aspirin regularly. Moving on, the focus shifts to brain injuries and how it affects young athletes, college-age and younger, with early neuron loss and CFE's. It's a finding that highlights long-term risk associated with sports, like football and soccer, leading to new guidelines for player safety and concussion protocols. More warnings on pregnancy and cannabis use, as use has climbed due to wider legalization and social acceptance, with many turning to marijuana to curb morning sickness and pregnancy pain symptoms. Lastly, new research explains a phenomenon how exercise suppresses appetite through a previously-unknown molecular pathway, questioning why bugs bite us, and the latest on the screwworm.  Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

Navigating Food, Body Image, and GLP-1 Medications: An Interview with Robyn L. Goldberg, RDN, CEDS-C Therapists are seeing more clients struggling with confusing medical advice, new medications, and diet culture messages that impact their relationship with food and body. In this conversation, Curt and Katie talk with Robyn L. Goldberg, RDN, CEDS-C about how therapists can examine their own biases, support clients navigating restrictive medical guidance, and encourage healthier, more intuitive approaches to eating. About Our Guest: Robyn L. Goldberg, RDN, CEDS-C Robyn began her career at Cedars-Sinai Medical Center in Los Angeles as the in-patient dietitian in the Department of Cardiology. Over the last twenty-eight years she has developed her own private practice in Los Angeles, CA. She is a contributing author and is a nationally and internationally known registered dietitian nutritionist. She has been quoted in The New York Times, The Huffington Post, and Vogue. She has been on national television as the eating disorder expert on The Insider. Robyn is the author of The Eating Disorder Trap: A Guide for Clinicians and Loved Ones, Co-author of the online course Your Recovery Resource, and the host of The Eating Disorder Trap Podcast. Key Takeaways for Therapists Therapists must examine their own food and body biases to avoid unintentional harm to clients. Many physicians have minimal training in dietetics and may give inadequate advice. Clients can advocate for themselves in medical settings, including refusing to be weighed. GLP-1 medications may reduce appetite but can cause malnutrition, fatigue, and bone/muscle loss. Intuitive eating offers a path back to a healthier, more trusting relationship with food. For full show notes and transcript: mtsgpodcast.com Join the Modern Therapist Community Linktree: https://linktr.ee/therapyreimagined Creative Credits Voice Over by DW McCann Music by Crystal Grooms Mangano

A bold trial in valvular heart disease, a CV prevention trial whose message is humility, VTE dogma challenged, more news on oral GLP-1 agonists, and a few public service announcements are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I DOUBLE-CHOICE: Minimalist Approach to TAVI May Be as Good as Standard of Care https://www.medscape.com/viewarticle/double-choice-minimalist-approach-tavi-may-be-good-standard-2025a1000pp7 Patient & Physician Perspectives on CV Risk https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011837 II KP Vaccinate Trial KP Vaccinate Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500208 IAMI trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057042 Increasing Flu Vaccinations in Patients With Chronic Disease https://jamanetwork.com/journals/jama/fullarticle/2824956 MI FREEE Trial https://www.nejm.org/doi/full/10.1056/NEJMsa1107913 III Hi PRO Trial Apixaban for Extended Treatment of VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2509426 Recurrent VTE in Patients with Provoked VTE https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/226140 IV Oral GLP-1 Agonists ATTAIN 1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent report of the use of phenoxybenzamine for the reduction of SVR in children undergoing congenital heart surgery in India. How does this agent work and what might be the advantage versus other agents like nitroprusside or milrinone which are more commonly used? How does the cost of this agent (or phentolamine) compare with newer agents? We speak with Dr. Rohit Loomba of Lurie Children's Hospital. For those interested, in addition to working as a critical care cardiologist, Dr. Loomba is also a noted cardiac morphologist and his wonderful videos can be seen at the following web address:https://www.youtube.com/@Talking_HeartsToday's paper:DOI: 10.4103/jpbs.jpbs_868_25

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Guest: David Majure, M.D., MPH On this episode of Advances in Care, host Erin Welsh talks to Dr. David Majure, a cardiologist and heart failure specialist at NewYork-Presbyterian and Weill Cornell Medicine. Together, they discuss the rapid rise in GLP-1 research over the past few years, indicating new applications for these therapies to help a wide variety of patients. They explore how GLP-1s work on a molecular level and how using them to treat diabetes revealed other potential cardiovascular benefits. Dr. Majure highlights several recent studies that explore the effects of semaglutide and tirzepatide on patients with heart failure, particularly those with preserved ejection fraction. This new research demonstrates that GLP-1s can be an effective treatment beyond diabetes, helping with weight management and cardiovascular disease. Dr. Majure breaks down what effects doctors can expect to see in patients who are prescribed GLP-1s, including the difference in outcomes between semaglutide and tirzepatide. He also notes the potential risk factors, cautioning that while these medications are effective, the focus in addressing heart disease should always remain on prevention. © 2025 NewYork-Presbyterian

The TCTMD team discusses their favorite stories from this past month, while special guest Robert Roswell breaks down the DAPT-SHOCK-AMI trial from ESC 2025.

In this powerful episode of Keeping Abreast, Dr. Jenn Simmons sits down with cardiologist Dr. Jack Wolfson to challenge the conventional wisdom on heart health. Together, they unpack the failures of mainstream cardiology, the risks of statins, and why true healing comes from addressing root causes—not masking symptoms with pharmaceuticals.From nutrition and stress management to environmental toxins and community support, Dr. Wolfson and Dr. Jenn explore the real drivers of cardiovascular health. They also discuss how COVID-19 reshaped the landscape of heart disease and why women face unique risks too often ignored in conventional medicine.This conversation is essential listening for anyone questioning the pill-for-every-ill approach, seeking practical steps for prevention, or wanting to reclaim ownership of their heart health.In This Episode, You Will Learn:Why cardiovascular disease remains the #1 killer worldwideHow pharmaceuticals often miss the root causeThe truth about statins and their limited benefitsThe central role of nutrition in heart healthHow stress and emotional health impact the heartWhy toxins in food, water, and air can drive diseaseThe dangers of rigid medical guidelinesThe overlooked link between breast cancer and heart diseaseWhy community and relationships protect cardiovascular healthHow women's unique risks demand a new approach

Message our hosts, Kieran and Jose.Season 3 of The Animal Heartbeat is all about the Veterinary Cardiology Icons - those who walk among us as legends of the veterinary cardiology world.In Episode 7 of the Icons series, Prof John Bonagura joins our hosts, Jose and Kieran, to discuss how we can advance our echocardiographic skills in animals. Echocardiography is a fundamental tool for clinicians and researchers, something we use every day to infirm decision making for our patients. But is one echo the same as the next? Can we do better to improve our accuracy of diagnosis, and is there a role for standardised echo guidelines? John discusses his career spanning experience of echocardiography, from M-mode to speckle tracking techniques and using real-time 4D volumes, and updates us on the progress of the joint ACVIM-ASE guidelines for 2D echo in animals, upcoming in 2026.Listen with us as Dr Bonagura shares his perspectives and takes a deep-dive on echo for the veterinary cardiologist.

More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I PARACHUTE HF First Evidence of Treatment Benefit in Chagas Heart Failure https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q DAPA ACT HF-TIMI 68 https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575 III AMALFI Trial of AF Screening Remote ECG Screening Ups Atrial Fibrillation Detection ‘Modestly' https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482 STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090 Variations in Rates of Stroke Across Patients With AF https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we replay an episode from 2 years ago on postoperative ectopic atrial tachycardia (EAT) following congenital heart surgery in children. Are there risk factors for this arrhythmia and are any modifiable? What is the 'go to' therapy used by the electrophysiologists at Children's LA for the acute and chronic treatment of this arrhythmia in the postoperative period? Is the presence of EAT in a postoperative congenital heart patient a marker for a worse outcome? These are amongst the questions posed to Children's of Los Angeles pediatric electrophysiologist, Dr. Jonathan Uniat. ·         DOI: 10.1007/s00246-022-03068-8

Updates on GLP-1 drugs in heart failure, β-blockers after myocardial infarction, the shingles vaccine, and more: Felix Mahfoud, MD, chair of the Department of Cardiology at University Hospital Basel, shares clinical research highlights from the recent European Society of Cardiology Congress. Related Content: GLP-1 Drugs in Heart Failure, β-Blockers After MI, the Shingles Vaccine, and More From ESC 2025

Please join HRS Digital Education Committee Vice-Chair, Tina Baykaner, MD, MPH, of Stanford University, as she is joined by Heart Rhythm Society President Mina K. Chung, MD, FHRS, of the Cleveland Clinic, and Konstantinos C. Siontis, MD, FHRS of the May Clinic. The three met up in Altanta at HRX 2025 for this stimulating coversation. This study evaluated whether artificial intelligence applied to single-lead ambulatory ECGs could predict imminent sustained ventricular arrhythmias. Using deep learning models, the researchers demonstrated that AI could identify subtle ECG features preceding arrhythmic events, enabling accurate short-term risk prediction. The findings suggest a potential role for AI-enhanced ECG monitoring to improve early detection and prevention of life-threatening ventricular arrhythmias. To view bonus video recorded LIVE at HRX 2025 in Atlanta, view this episode on Heart Rhythm 365 or the HRX Innovation Hub! Article Authors Laurent Fiorina ∙ Tanner Carbonati∙ Kumar Narayanan ∙ Jia Li ∙ Christine Henry ∙ Jagmeet Singh ∙ Eloi Marijon Read the Article: https://www.heartrhythmjournal.com/article/S1547-5271(23)02195-1/fulltext Podcast Contributors and Disclosures Tina Baykaner, MD, MPH | Stanford University Mina K. Chung, MD, FHRS | Cleveland Clinic Konstantinos C. Siontis, MD, FHRS | Mayo Clinic All relevant financial relationships have been mitigated. T. Baykaner:   •Honoraria/Speaking/Consulting: Volta Medical, Medtronic, Pacemate, Johnson and Johnson, Abbot Medical, Boston Scientific Research: NIH M. Chung: •Honoraria/Speaking/Consulting: University of Chicago, Cedars Sinai Medical Center, Asia Pacific Heart Rhythm Society, NIH, Baylor College of Medicine, Kansas City Heart Rhythm Symposium, American College of Cardiology, Geisinger Health Systems, ABIM, Academy for Continued Healthcare Learning, MediasphereMedical, Western AF Symposium, University of Minnesota, Stanford University, Canadian Heart Rhythm Society •Research: NIH, American Heart Association •Royalty Income: Elsevier, Wolters Kluver •Officer: American Heart Association K. Siontis: •Research: Anumana, Varian Medical Systems •Intellectual Property Right: Anumana •Speaking/Teaching/Consulting: EBAMedSA, AskBio

The Upsurge in Chronic Heart Failure & What We Can Do About It, with Waqas Ghumman, MD Head of the Advanced Heart Failure & Transplant Cardiology Department at JFK, HCA

Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken discuss the biggest news stories in the medical world, starting with a focus on a risk factor of high blood pressure in children, the need for blood pressure to be monitored earlier in life,  and a report of the overall health in children and addressing childhood chronic diseases due to ultra processed foods, vaccine policies, lack of exercise and chemical exposure. Then the conversation shifts to the weight loss drug Mounjaro/Zepbound may be able to shrink breast cancer tumors as proven in a study with mice. It's an unexpected finding which may lead to a potential, new therapeutic use for the drug beyond it's current application for obesity and diabetes. Next, Florida makes news after the announcement was made of the state lifting school vaccine mandates, there's a new hope for people suffering from mental health issues with a new, monthly-injectable drug had been approved for Schizophrenia and Bipolar 1 Disorder, and time spent sitting on the toilet is at an all-time high due to phone use — leading to a 46% higher rate of hemorrhoids. The conversation rounds out with listener questions for Dr. Ken, including an increased requirement for pre-approval for medical tests, how to know what doctor to go see in a world now full of specialists and debating what insurance will cover, the need for a quality primary care provider, and learning about the common skin condition called eczema.  Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

Bongani Bingwa speaks with Dr. David Jankelow, Cardiologist and Past President of the South African Heart Association about whether Artificial Intelligence (AI) could help address the country’s heart disease crisis, its potential impact on underserved areas, and the South African Heart Association’s plans to screen the health of taxi drivers and commuters in Soweto. 702 Breakfast with Bongani Bingwa is broadcast on 702, a Johannesburg based talk radio station. Bongani makes sense of the news, interviews the key newsmakers of the day, and holds those in power to account on your behalf. The team bring you all you need to know to start your day Thank you for listening to a podcast from 702 Breakfast with Bongani Bingwa Listen live on Primedia+ weekdays from 06:00 and 09:00 (SA Time) to Breakfast with Bongani Bingwa broadcast on 702: https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/36edSLV or find all the catch-up podcasts here https://buff.ly/zEcM35T Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

Good morning friends and neighbors! This morning we are excited to welcome new guests to our program and to talk about an awesome upcoming event. On Friday, September 26th The RUSH Copley Foundation will host this year's Rock The Heart event at Two Brothers Roundhouse in Aurora.Today we will be speaking with Alexander Pope, Chief Development Officer and VP of Philanthropy and Community Engagement and Carmen Kaufman, Physician Assistant in Cardiology. Got questions? Send us an email to: goodmorningaurorail@gmail.comHave a great rest of the day! Good Morning Aurora will return with more news, weather and the very best of Aurora. Subscribe to the show on YouTube at this link: https://www.youtube.com/c/GoodMorningAuroraPodcastThe second largest city's first daily news podcast is here. Tune in 5 days a week, Monday thru Friday from 9:00 to 9:30 am. Make sure to like and subscribe to stay updated on all things Aurora.Threads: https://www.threads.net/@goodmorningaurorailInstagram: goodmorningaurorailSpotify: https://open.spotify.com/show/6dVweK5Zc4uPVQQ0Fp1vEP...Apple: https://podcasts.apple.com/.../good-morning.../id1513229463Anchor: https://anchor.fm/goodmorningauroraACTV (Aurora Community Television): https://www.aurora-il.org/309/Aurora-Community-TV#kanecountyil #bataviail #genevail #elginil #aurorail #auroraillinois #cityofaurorail #auroramedia #auroranews #morningnews #goodmorningaurora #tuesday #fyp

Identifying and managing PAD requires a head-to-toe strategy. Guest Tiffany Staab, RN, FNP, MSN, describes the four PAD stages, how the disease disproportionately affects Black patients, and the importance of listening to patient symptoms and observing lower limbs to help stem the tide of PAD-related amputations.PCNA PAD resources: https://pcna.net/health-topics/pad/AHA PAD heat map: https://professional.heart.org/en/education/pad-for-professionals/pad-collaborative/heat-mapSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The 2021 winner of the Nobel Prize in medicine, Ardem Patapoutian speaks of his love for science, why he wishes he had an MD, and the importance of getting out of the lab to inspire young people. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit: https://www.medscape.com/author/bob-harrington Nobel Prize in Physiology or Medicine 2021 https://pubmed.ncbi.nlm.nih.gov/39429349/ https://www.nobelprize.org/prizes/medicine/2021/press-release/ Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels https://pubmed.ncbi.nlm.nih.gov/20813920/ PIEZOs mediate neuronal sensing of blood pressure and the baroreceptor reflex https://doi.org/10.1126/science.aau6324 PIEZO Ion Channels in Cardiovascular Functions and Diseases https://doi.org/10.1161/CIRCRESAHA.123.322798 You may also like: Hear John Mandrola, MD, with his summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

With Børge Nordestgaard and Anders Berg Wulff, Copenhagen University Hospital, Copenhagen - Denmark. Read the European Heart Journal - Cardiovascular Imaging paper Read the European Heart Journal - Cardiovascular Imaging editorial

More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I New European Valvular Heart Disease Guidelines 2025 ESC/EACTS Guidelines for the management of valvular heart disease  https://doi.org/10.1093/eurheartj/ehaf194 Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/ Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528 Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336 II  New Drug for Resistant HTN Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7 Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109 Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440 III HCM News at ESC New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654 SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424 ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927 IV Vericiguat at ESC New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9 VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4 VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928 An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4 V More on Digoxin RATE AF substudy https://doi.org/10.1002/ejhf.70022 Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407 Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent report from the Boston Children's team on their 39 year experience managing and caring for children with myocardial infarction following Kawasaki disease (KD). What were the clinical features of KD patients that were most associated with this rare complication? What signs or symptoms should be concerning for the caregiver of patients with KD? What are the more common approaches to the management of MI in this fragile and young patient population? Dr. Sunil Ghelani of Boston Children's Hospital offers the answers this week. DOI: 10.1016/j.jpeds.2025.114638

Last week, John was at the European Society of Cardiology conference in Madrid, and Adam was at the Preventing Overdiagnosis 2025 International Conference in Oxford. A conversation about what we learned.Digitoxin in Patients with Heart Failure and Reduced Ejection FractionBeta-Blockers Post-MI: A Clear Clinical MessageAspirin in Patients with Chronic Coronary Syndrome Receiving Oral AnticoagulationHow does decontextualised risk information affect clinicians' understanding of risk and uncertainty in primary care diagnosis? A qualitative study of clinical vignettesHow do we talk about overdiagnosis of mental health conditions without dismissing people's suffering? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

Lauren Rosenberg, a highly experienced Physician Associate, has dedicated nearly two decades to Internal Medicine and Health Optimization. Driven by a passion for preventative care, Lauren founded Vent Health to shift the focus from disease treatment to prevention. She specializes in a personalized approach that blends genetics, epigenetics, biomarkers, and lifestyle factors to tailor health interventions that extend and optimize each patient's healthspan. Lauren's practice includes prescribing peptides (GLP, CLP/GIP) for weight loss, insulin resistance, pre-diabetes, etc.  This episode concentrates on MENOPAUSE. Lauren and Heather discuss what symptoms could be related to Menopause.  Lauren will speak about hot flashes, heart palpitations, frozen shoulder, brain fog, lack of libido, itchy ears, anxiety, trouble sleeping, hair changes, urinary tract infections. They will discuss what can you do at home and what treatments can be beneficial from professionals, such as GLP 1's for weight gain and  hormone replacement options.  Lauren is a frequent speaker at the Age Management Medicine Group (AMMG) and the American Academy of Anti-Aging Medicine (A4M) conferences.  Lauren's practice includes Cardiology prevention: Diagnostics and AI analysis to detect dangerous plaque and calcium; advanced lipid testing and cardiovascular genetics Longevity biomarkers: DNA methylation for biological age, VO2 max testing, Telomere health; Therapeutic plasma exchange Cancer prevention: methylated DNA screens, preventative MRIs, tumor marker testing.  Lauren's Website:     https://myventhealth.com/about/ Heather's Website: www.heatherthomson.com Social Media: IG: https://www.instagram.com/iamheathert/                     You Tube: https://youtube.com/@iamheathert?si=ZvI9l0bhLfTR-qdo SPONSORS:  BLISSY: Blissy is offering 60-nights risk-free PLUS an additional 30% off when you shop at www.Blissy.com/HEATHERPOD and use code HEATHERPOD. Your hair and skin will thank you! AIRDOCTOR: Go to AirDoctorPro.com and use promo code HEATHER to get UP TO $300 off today! AirDoctor comes with a 30-day money back guarantee, plus a 3-year warranty—an $84 value, free! Get this exclusive, podcast-only offer now at www.AirDoctorPro.com using promo code HEATHER. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. John Osborne of Clear Cardio, a Preventative Cardiologist, talks about how you can take charge of your heart health before problems arise. Dr. Osborne shares why prevention is the best medicine, practical steps you can take to lower your risk of cardiovascular disease, and the latest insights on lifestyle and early detection. Learn more at https://clearcardio.com/Bio:Dr. John Osborne is not your typical cardiologist.He's one of fewer than 50 Cardiologist out of 33,000 in the U.S. triple board-certified in Cardiology, Lipidology, and Hypertension — and one of only a handful globally trained to interpret the most advanced heart imaging on the planet.But what truly sets him apart is how he practices.With a PhD in Cardiovascular Physiology and more than 25,000 advanced heart scans performed, Dr. Osborne has spent the last 25 years developing a completely different approach to heart health — one that's holistic, non-invasive, and deeply human.He's the co-founder of ClearCardio™, a revolutionary prevention-first annual heart disease, detection and treatment practice that detects disease before symptoms show up — and reverses it without surgery or scare tactics.His method blends AI-powered diagnostics with lifestyle medicine, medication precision, and deep listening. He looks at the full person — genetics, stress, sleep, hormones, nutrition, environment — not just lab numbers.He believes heart attacks are largely preventable.And that your body, when given the right tools, already knows how to heal.For more information about Laura and her work you can go to her website www.healingpowers.net or find her on X @thatlaurapowers, on Facebook at @realhealingpowers and @mllelaura, and on Instagram, TikTok and Insight Timer @laurapowers44.

Cardiology nurse + NY FASHION WEEK MODEL, Chris Franz (@chrsfranz, host of Friends of Franz Podcast) joins me to share his story of what was never said, to a dear friend who passed away recently. We chat about: - the behind the scenes of NY fashion week, from walking the runway to editorial shoots, being in Harpars Bazaar, and the art/job that modeling is - adult friendships: why they are so hard to replicate the intimacy of close childhood and school friends- why we always think we have more time than we do, and how to not let life get in the way - the power of letting grief be a sign of the strength of a relationship IG: @drconniewang, @justsquickpinch

Welcome to Ozempic Weightloss Unlocked. Today we dive into the latest headlines, research, controversies, and the practical realities of Ozempic, a medication originally crafted for type two diabetes that has rocketed into the spotlight for its weight-loss effects.Ozempic, with the active ingredient semaglutide, was approved in the United States in December 2017 to help manage blood sugar in people living with type two diabetes. However, it soon became widely prescribed off-label for weight loss, a trend that only accelerated after the higher-dose version, branded as Wegovy, received federal approval in 2021. According to the Lawsuit Information Center, Ozempic works by mimicking a hormone called glucagon-like peptide 1, helping regulate blood sugar and appetite. Many people using it experience reduced appetite and significant weight reduction.While its popularity continues to grow, so does scientific understanding. A 2025 study presented at the European Society of Cardiology conference revealed that Swiss patients with type two diabetes using oral semaglutide experienced clinically significant drops in both blood sugar and body weight. GlobalData reports that no new safety risks were identified in that trial, supporting ongoing confidence among healthcare professionals.But for those interested only in weight loss, it is not all smooth sailing. Ozempic carries a range of potential side effects. According to King Law, hundreds of lawsuits have been filed in the last year, with plaintiffs claiming they suffered severe complications such as gastroparesis, intestinal blockages, blood clots, and even hair loss. A study published this August found that women on Ozempic experienced twice the rate of hair loss as women who were not taking the drug, while men saw their risk climb by more than half.The United States Food and Drug Administration updated Ozempic's packaging earlier this year to warn about the risk of pancreatitis and severe kidney injuries, including potentially fatal outcomes linked to dehydration from vomiting and diarrhea. The label changes were driven by new clinical trial data and reinforce the importance of medical supervision when using these drugs.Shortages, once a common concern, have eased. The Food and Drug Administration officially took Ozempic off the drug shortage list in February after Novo Nordisk provided reassurance about inventory and supply. That move, however, sparked legal challenges from compounders competing in the market.Unfortunately, enthusiasm for rapid weight loss has also created a black market for Ozempic and similar drugs. The Food and Drug Administration cautions against using compounded or counterfeit versions, which have not undergone review for safety or effectiveness. Some of these unregulated products might be contaminated, mislabeled, or dangerously dosed. Always fill your prescriptions through a licensed pharmacy.For listeners interested in alternatives, exciting research is underway. Purdue University food scientists are investigating foods and supplements that naturally stimulate GLP-1, the hormone Ozempic is designed to mimic. While these approaches will not produce the dramatic weight loss seen with medication, they may help those seeking more natural solutions—especially if someone discontinues their prescription and needs help maintaining a healthy weight.So, where does Ozempic stand today? We have a medication achieving strong results for blood sugar control and weight loss, but one that comes with a profile of side effects still being researched, legal actions underscoring patient concerns, and increased focus on responsible, safe prescribing.Thank you for tuning in to Ozempic Weightloss Unlocked. For more news, insights, and emerging research on the evolving world of weight loss and metabolic health, be sure to subscribe. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

In this fascinating episode of Parallax, Dr Ankur Kalra sits down with Dr Alexander Fanaroff, an interventional cardiologist, clinical trialist, and behavioral economist at the University of Pennsylvania. Dr Fanaroff brings a unique perspective to cardiovascular medicine, combining his expertise in interventional cardiology with cutting-edge insights from behavioral economics to transform how we approach patient care and clinical decision-making. Dr Fanaroff demystifies behavioral economics for the medical community, explaining how this field studies real-world decision-making beyond traditional economic models. He introduces key concepts like status quo bias, prospect theory, and the power of defaults in shaping both physician and patient behaviors. Through compelling examples, including Penn's successful intervention that increased 90-day statin prescriptions from 70% to 90% simply by changing EHR defaults, Dr Fanaroff demonstrates how small design changes can yield significant clinical improvements. Looking beyond individual interventions, Dr Fanaroff discusses how behavioral economics can address healthcare disparities by creating system-wide improvements that lift all patients while specifically targeting underserved communities. He envisions a future where AI identifies at-risk patients from routine imaging, and where interventional cardiologists focus not just on procedural excellence but on ensuring optimal long-term medical management through thoughtfully designed care systems. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

Message our hosts, Kieran and Jose.Season 3 of The Animal Heartbeat is all about the Veterinary Cardiology Icons - those who walk among us as legends of the veterinary cardiology world.In this episode, we welcome Prof Kate Meurs, Randall B. Terry Jr Dean of North Carolina State University College of Veterinary Medicine. Prof Meurs has worked across the fields of clinical vet cardiology and genetics, and drove the research that led to the discovery of mutations associated with HCM in cats, DCM and ARVC in dogs, and arrhythmia-induced death in particular canine family lines. Her work has changed how we think about heart disease in companion animals, and may hold the key to future refinements in the care we provide for animals with heart disease.Listen to Prof Meurs' reflections on her groundbreaking work, and her thoughts on how we can best use genetic testing to help maximise animal wellbeing in the clinic.

Neste episódio, você confere a revisão sistemática sobre o uso de corticoides em pneumonia comunitária grave, os novos critérios diagnósticos de pericardite do American College of Cardiology, os atalhos cognitivos preciosos para identificar a demência rapidamente progressiva, as atualizações sobre doença renal diabética e o guideline brasileiro de 2025 sobre tuberculose em pacientes com doenças inflamatórias imunomediadas (DIIM).Leia na íntegra os artigos mencionados hoje:Corticoide para pneumonia comunitária gravePericardite: Novos critérios diagnósticos do American College of CardiologyDemência rapidamente progressiva: atalhos cognitivos preciososDoença renal diabética: novos conceitosGuideline brasileiro de 2025 sobre tuberculose em pacientes com DIIM (em breve no Portal Afya) #ClínicaMédica #CheckUpSemanal #Pneumonia #Pericardite #Demência #DoençaRenalDiabética #Tuberculose #Medicina

The big beta-blocker story from ESC, dual pathway therapy with aspirin and OAC, stopping OAC after successful AF ablation, and DANCAVAS II trial are the topics John Mandrola, MD, discusses on this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback This Week in Cardiology Podcast – August 29 https://www.medscape.com/viewarticle/1002877 II The Big Beta-blocker Story from ESC Beta-Blockers Post-MI: A Clear Clinical Message https://www.medscape.com/viewarticle/beta-blockers-post-mi-clear-clinical-message-2025a1000mz0 REBOOT https://www.nejm.org/doi/full/10.1056/NEJMoa2504735 BETAMI-DANBLOCK https://www.nejm.org/doi/abs/10.1056/NEJMoa2505985 REDUCE AMI https://www.nejm.org/doi/10.1056/NEJMoa2401479 CAPITAL RCT https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347 Post Hoc Analysis From REBOOT Trial https://eurointervention.pcronline.com/article/effect-of-beta-blocker-withholding-or-withdrawal-after-myocardial-infarction-without-reduced-ejection-fraction-on-ischaemic-events-a-post-hoc-analysis-from-the-reboot-trial Beta-Blockers After MI With Mildly Reduced Ejection Fraction https://doi.org/10.1016/S0140-6736(25)01592-2 CAPRICORN 10.1016/S0140-6736(00)04560-8 External Link BHAT https://jamanetwork.com/journals/jama/fullarticle/370103 ISIS 1 https://pubmed.ncbi.nlm.nih.gov/2873379/ III Aspirin and OAC Combination Clearly Dangerous Aspirin Plus Oral Anticoagulants Raises Mortality, Bleeding https://www.medscape.com/viewarticle/aspirin-plus-oral-anticoagulants-raises-mortality-bleeding-2025a1000nam AQUATIC https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 AFIRE https://www.nejm.org/doi/full/10.1056/NEJMoa1904143 EPIC CAD https://www.nejm.org/doi/10.1056/NEJMoa2407362 OAC-ALONE  https://pubmed.ncbi.nlm.nih.gov/30586700/ IV Stop or Continue OAC after Successful AF Ablation ALONE-AF https://jamanetwork.com/journals/jama/fullarticle/2838294 OCEAN trial protocol https://doi.org/10.1016/j.ahj.2017.12.007 V DANCAVAS II Trial DANCAVAS II https://doi.org/10.1093/eurheartj/ehaf704 DANCAVAS I https://www.nejm.org/doi/full/10.1056/NEJMoa2208681 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

If you're interested in boosting your cardiovascular fitness, I've got three steps for you to do.  Your cardiovascular fitness - VO2 max - is the most powerful predictor of longevity. Together with your lower body strength, they will tell the story of your future.    What is VO2 max? Oxygen consumed in milliliters per kilogram per minute. Strongest predictor of longevity, alongside lower body strength. VO2 Max and muscle mass peaks typically at age 25, with studies suggesting an average annual reduction of about 1% after.   Increasing your VO2 max can significantly increase your longevity. It can reduce all-cause mortality by 10-25%. Just going from low to above-average fitness levels can reduce mortality risk by 60-70% over a decade.    The 3 Steps to Improve Cardio Fitness 1. Long slow aerobic exercise  Walking, hiking, biking, swimming. Work just below threshold (can talk, slightly breathy). 80% of the time will be spent here. 20% should be spent doing HIIT or strength training. 2. High-Intensity Interval Training (HIIT)  10-15% improvement in 5-10 weeks 15–30 seconds of breathless effort (sprinting effect). Breathless in 30 seconds or less. 3. Strength training Improves muscle, may enhance your body composition or weight    Improving both your fitness (oxygen delivery and use) and reducing weight means your ml/kg/min will go up as you consume more oxygen with less body weight .. and even if you don't lose weight your muscle is metabolically active and consumes oxygen while fat doesn't.    So let's come back to the value of VO2 for reducing all cause mortality.  A modest increase of 3.5 ml/kg/min (1 MET) is all it takes to reduce all-cause mortality by up to 25%.    How do you know your Cardio Fitness is improving?    Short of getting a VO2 max test, you can measure in other ways:  Resting heart rate – first thing in morning  Recovery heart rate at end of interval and one minute later One-mile walk test   Why Muscle Still Matters? More muscle = higher oxygen demand → better VO2 Max. Fat mass doesn't contribute to oxygen use. Muscle quality declines with age → requires smarter training, especially during menopause.   Watch this episode on Flipping50TV YouTube.   References:  Journal of American College of Cardiology. 2018, PMID: 30384883. Circulation. 2007, PMID: 17548726.   Other Episodes You Might Like: Previous Episode - 80 Lb Perimenopausal Weight Loss After Corporate Burnout Next Episode - From Your Mouth to Your Gut: Hearing Health Whisper More Like This - Extended Cardio and Low Protein Equal Short Term Weight Loss   Resources:  Join the Hot, Not Bothered! Challenge to learn why timing matters and why what works for others is not working for you. Use Flipping 50 Scorecard & Guide to measure what matters with easy at-home self-assessment test you can do in minutes. Are you burning belly fat or burning out? Get the Menopause Fitness Guide to High-Intensity Interval Training to help you lose more fat and stay on track!  

This week we review a landmark paper that came out this month on the topic of ACHD. How common is neurocognitive dysfunction amongst the ACHD patient population? What factors are associated with worse or better such outcomes? What interventions should be considered to mitigate these issues? What is the relationship between mental illness and neurocognitive dysfunction? Dr. Scott Cohen of The Medical College of Wisconsin and Dr. Ali Zaidi of The Icahn School of Medicine at Mount Sinai share their insights into their recent multicenter study. doi: 10.1016/j.jacc.2025.06.051Also featured after the article is a brief description of the upcoming Mount Sinai ACHD Conference called: Kawasaki Disease Across The Ages: From Childhood Onset To Adult Outcomes - The 4th Mount SInai ACHD Symposium. We speak with Dr. Nadine Choueiter who is the Course Director of this conference about the goals and objectives of the conference. Dr. Zaidi is the course co-director. For those interested in signing up, please go to this webpage:https://physicians.mountsinai.org/news/register-today-for-the-fourth-annual-mount-sinai-adult-congenital-heart-disease-symposium

In this episode, Drs. Laura Onderko, Zain Asad, and Aditya Bharadwaj delve into how fellows-in-training and early-career cardiologists can strategically build their research careers and assess whether academic medicine is the right fit. The conversation highlights diverse pathways for engaging in research—from participating in clinical trials to securing grant funding—and explores the valuable resources offered by the American College of Cardiology to support aspiring physician-scientists.   Subscribe to PracticeMadePerfect|  

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Ahmet Bilgili, from the University of Florida's Congenital Heart Center, and senior author Eric I. Jeng, MD, from the University of Florida's MCS program. Bilgili and Dr. Jeng discuss their paper, “Optimal pretransplant duration with HeartMate III left ventricular assist device: A contemporary analysis.” The discussion explores: Prior gaps in the literature regarding contemporary HM3 outcomes in relation to transplantation—and the study's potential influence on policy Which length of HM3 support influenced better post-transplant outcomes—and which ages were most influenced How these findings might change standard practice For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

Send us a textDr. Michael Koren joins Kevin Geddings to report live from Madrid on new developments being presented at the European Society of Cardiology meeting. This medical gathering, now the world's largest, is a showcase of developments in heart health and medicine. Dr. Koren notes excitement about progress in treating a genetic condition, lipoprotein(a), which raises cholesterol independently from diet and exercise. He notes that progress in this field is showing promise and that those with a family history of heart disease should have their lipoprotein(a) checked!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

CAC 0 takes a gut punch, ICD therapies cannot be surrogates for benefit, and two important trials from ESC are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I CAC 0 LDL-C and CVD Risk With CAC Score 0 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf497/8228645 II ICD Therapies Contemporary ICD Benefit https://www.jacc.org/doi/10.1016/j.jacep.2025.06.028 PROFID Trial https://profid-project.eu/profid-ehra-trial/ MADIT-RIT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1211107 Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 III Digit-HF DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471 Digoxin–Mortality: Comparison in the DIG trial https://academic.oup.com/eurheartj/article/40/40/3336/5520008 IV POTCAST POTCAST trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509542 ESC Preview IV HTN Guidelines New Blood Pressure Guidelines: 4 Things I Like and 2 Concerns  https://www.medscape.com/viewarticle/new-blood-pressure-guidelines-4-thing-i-and-2-concerns-2025a1000m1x You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This year is the 50th anniversary of the first transcatheter ASD closure in a human. To celebrate this achievement, this week we air a live interview from PICS 2025 in Chicago (conducted 8/26/25) with living interventional cardiology legend Dr. Terry King speaking about the events surrounding his landmark intervention as the first person to ever perform a transcatheter ASD closure with his partner, surgeon Dr. Noel Mills. In this one on one interview, Dr. King discusses how he came up with this idea with Dr. Mills and how he found a patient in which to proceed. He reviews what 'informed consent' was in 1975 and also how he and Dr. Mills accurately estimated ASD size in an era that preceded 2D echocardiography. Dr. King speaks about the role of family in his life and offers advice to the next generation. Finally, he shares with us what he is up to today and why he does not believe in retirement. Prepare to be excited and inspired by this wonderful figure in our field. 

In this very informative and enlightening interview, Dr. Eric Plasker and Dr. Stephen Hussey talk about how to create a truly healthy heart. They share their profound personal experiences and take a deep dive into heart health, revealing important insights that many cardiologists do not discuss. This includes the importance of advocating for yourself, having an advocate to support you, the importance of the sun, infrared heat, and light, chiropractic care, good nutrition, as well as the dangers of statin drugs and the mislabeling of many cardiac causes and conditions.Dr. Hussey has written three books, is a 100 Year Lifestyle Certified doctor, and provides educational courses to educate you and your family on holistic healing and optimum health. His website is... https://resourceyourhealth.comTheir common bond and personal experiences deliver a very strong message with a lot of very useful information to help YOU and YOUR LOVED ONES LIVE YOUR IDEAL 100 YEAR LIFESTYLE.@100yearlifestyle@drstephenhussey#100yearlifestyle #understandingtheheart #Stephenhussey #cholesterol #statins #infraredligt #structuredwater #chiropractic #ericplasker #100percentThe 100 Year Lifestyle Podcast

In this essential episode of Parallax, Dr Ankur Kalra welcomes Dr Shelley Zieroth, Professor of Medicine, clinician-scientist, and advanced heart failure and transplant cardiologist in Winnipeg, Canada. As we mark the 10-year anniversary of the landmark EMPA-REG OUTCOME trial, Dr Zieroth provides a comprehensive update on how SGLT2 inhibitors have revolutionized cardiovascular care. Dr Zieroth takes us through the remarkable journey from the initial 2015 trial that transformed SGLT2 inhibitors from anti-diabetic agents into cardiovascular powerhouses, delivering highly significant reductions in cardiovascular death and heart failure hospitalization. She explores how these medications have become fundamental pillars of cardio-kidney-metabolic medicine, with evidence spanning the entire ejection fraction spectrum. Dr Zieroth discusses prescribing these agents in heart failure - including the straightforward 10-mg daily dosing, monitoring strategies, and crucial patient selection criteria. She shares insights from the recent EMPULSE trial on safe in-hospital initiation, addresses important considerations for diabetic patients, and highlights key contraindications like indwelling catheters that clinicians must recognize. Beyond the basics, Dr Kalra and Dr Zieroth examine the evolving role of SGLT2 inhibitors in valvular disease and diastolic dysfunction, tackle the ongoing reimbursement challenges across different healthcare systems, and discuss the critical importance of multidisciplinary collaboration in the cardio-kidney-metabolic space. They also look ahead to exciting combination therapies on the horizon that promise to further advance heart failure prevention and treatment. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

A silent danger lurks within the descending thoracic aorta. While most Type B aortic dissections are managed medically, up to half of these patients will either require life-saving surgery or die within just five years. So how do we separate those who will quietly recover from those on the edge of catastrophe? How do we protect the spinal cord, bowel, and limbs from the devastating consequences of malperfusion? Join the University of Michigan Department of Vascular Surgery as they tackle the high-stakes decisions behind managing this unpredictable disease—where timing is critical, interventions are evolving, and lives hang in the balance. Hosted by the University of Michigan Department of Vascular Surgery: ·       Robert Beaulieu, Program Director ·       Frank Davis, Assistant Professor of Surgery ·       Luciano Delbono, PGY-5 House Officer ·       Andrew Huang, PGY-4 House Officer ·       Carolyn Judge, PGY-2 House Officer Learning Objectives: 1.         Discuss general approach to diagnosis and management of TBAD. 2.         Identifying high-risk features in uncomplicated TBAD and understanding their role in determining the need for surgical management. 3.         Review endovascular techniques for managing malperfusion of the limbs, viscera, and spinal cord and discuss associated decision making. References:  Authors/Task Force Members, Czerny, M., Grabenwöger, M., Berger, T., Aboyans, V., Della Corte, A., Chen, E. P., Desai, N. D., Dumfarth, J., Elefteriades, J. A., Etz, C. D., Kim, K. M., Kreibich, M., Lescan, M., Di Marco, L., Martens, A., Mestres, C. A., Milojevic, M., Nienaber, C. A., … Hughes, G. C. (2024). EACTS/STS Guidelines for Diagnosing and Treating Acute and Chronic Syndromes of the Aortic Organ. The Annals of Thoracic Surgery, 118(1), 5–115. https://doi.org/10.1016/j.athoracsur.2024.01.021 de Kort, J. F., Hasami, N. A., Been, M., Grassi, V., Lomazzi, C., Heijmen, R. H., Hazenberg, C. E. V. B., van Herwaarden, J. A., & Trimarchi, S. (2025). Trends and Updates in the Management and Outcomes of Acute Uncomplicated Type B Aortic Dissection. Annals of Vascular Surgery, S0890-5096(25)00004-4. https://doi.org/10.1016/j.avsg.2024.12.060 Eidt, J. F., & Vasquez, J. (2023). Changing Management of Type B Aortic Dissections. Methodist DeBakey Cardiovascular Journal, 19(2), 59–69. https://doi.org/10.14797/mdcvj.1171 Lombardi, J. V., Hughes, G. C., Appoo, J. J., Bavaria, J. E., Beck, A. W., Cambria, R. P., Charlton-Ouw, K., Eslami, M. H., Kim, K. M., Leshnower, B. G., Maldonado, T., Reece, T. B., & Wang, G. J. (2020). Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) reporting standards for type B aortic dissections. Journal of Vascular Surgery, 71(3), 723–747. https://doi.org/10.1016/j.jvs.2019.11.013 MacGillivray, T. E., Gleason, T. G., Patel, H. J., Aldea, G. S., Bavaria, J. E., Beaver, T. M., Chen, E. P., Czerny, M., Estrera, A. L., Firestone, S., Fischbein, M. P., Hughes, G. C., Hui, D. S., Kissoon, K., Lawton, J. S., Pacini, D., Reece, T. B., Roselli, E. E., & Stulak, J. (2022). The Society of Thoracic Surgeons/American Association for Thoracic Surgery Clinical Practice Guidelines on the Management of Type B Aortic Dissection. The Annals of Thoracic Surgery, 113(4), 1073–1092. https://doi.org/10.1016/j.athoracsur.2021.11.002 Papatheodorou, N., Tsilimparis, N., Peterss, S., Khangholi, D., Konstantinou, N., Pichlmaier, M., & Stana, J. (2025). Pre-Emptive Endovascular Repair for Uncomplicated Type B Dissection—Is This an Option? Annals of Vascular Surgery, S0890-5096(25)00007-X. https://doi.org/10.1016/j.avsg.2025.01.003 Trimarchi, S., Gleason, T. G., Brinster, D. R., Bismuth, J., Bossone, E., Sundt, T. M., Montgomery, D. G., Pai, C.-W., Bissacco, D., de Beaufort, H. W. L., Bavaria, J. E., Mussa, F., Bekeredjian, R., Schermerhorn, M., Pacini, D., Myrmel, T., Ouzounian, M., Korach, A., Chen, E. P., … Patel, H. J. (2023). Editor's Choice - Trends in Management and Outcomes of Type B Aortic Dissection: A Report From the International Registry of Aortic Dissection. European Journal of Vascular and Endovascular Surgery: The Official Journal of the European Society for Vascular Surgery, 66(6), 775–782. https://doi.org/10.1016/j.ejvs.2023.05.015 Writing Committee Members, Isselbacher, E. M., Preventza, O., Hamilton Black Iii, J., Augoustides, J. G., Beck, A. W., Bolen, M. A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., Collins, T. J., DeAnda, A., Fanola, C. L., Girardi, L. N., Hicks, C. W., Hui, D. S., Jones, W. S., Kalahasti, V., … Woo, Y. J. (2022). 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 80(24), e223–e393. https://doi.org/10.1016/j.jacc.2022.08.004 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

John Mandrola discusses conduction system pacing vs standard pacing, withdrawing HF meds when AF is corrected and patient selection in LAAO. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Conduction System Pacing CSPACE trial https://doi.org/10.1016/j.jacc.2025.06.043 BLOCK HF trial https://www.nejm.org/doi/full/10.1056/NEJMoa1210356 BioPace trial https://doi.org/10.1093/europace/euaf029 II  Withdrawing Meds After AF Corrected WITHDRAW AF https://doi.org/10.1093/eurheartj/ehaf563 TRED HF https://pubmed.ncbi.nlm.nih.gov/30429050/ III Patient Selection in Left Atrial Appendage Occlusion Long-Term Outcomes Following LAAO in Medicare Beneficiaries: Outcomes From the National Cardiovascular Data Registry https://www.ahajournals.org/doi/10.1161/JAHA.124.039780 ESC Preview IV HTN Guidelines New Blood Pressure Guidelines: 4 Things I Like and 2 Concerns https://www.medscape.com/viewarticle/new-blood-pressure-guidelines-4-thing-i-and-2-concerns-2025a1000m1x You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent work addressing the growing mismatch between the numbers of ACHD patients and the numbers of well trained ACHD providers. What are the most important factors influencing trainees' decisions regarding the pursuit of a career in ACHD? How can more young people be influenced to pursue this fascinating and growing field? We speak with Dr. Katia Bravo-Jaimes of The Mayo Clinic in Jacksonville, FLA about a recent survey study she conducted on the factors that influenced these important decisions. Dr. Bravo-Jaimes shares her thoughts on solutions to increase the ACHD workforce.https://doi.org/10.1161/jaha.125.041276

Big new hypertension guidelines, ultraprocessed foods, coronary sinus reduction and evidence-based medicine, and more news on pulsed field ablation for atrial fibrillation are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I HTN Guidelines BP Meds Should Begin Promptly, New ACC/AHA Guidelines Say https://www.medscape.com/viewarticle/bp-meds-should-begin-promptly-new-acc-aha-guidelines-say-2025a1000lms Guideline for Management of High Blood Pressure https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356 BPROAD trial https://www.nejm.org/doi/full/10.1056/NEJMoa2412006 Trial Score Framework https://pmc.ncbi.nlm.nih.gov/articles/PMC6459598/ II UltraProcessed Foods AHA statement on Ultraprocessed Foods and Cardiometabolic Health https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001365 III Refractory Angina and the Coronary Sinus Reducer – A Lesson in EBM Coronary Sinus Reducer Shows Promise, With Caveats https://www.medscape.com/viewarticle/coronary-sinus-reducer-shows-promise-caveats-2025a1000l76 Coronary Sinus Reducer — Meta-analysis https://www.jacc.org/doi/10.1016/j.jcin.2025.06.012 COSIRA II Trial https://clinicaltrials.gov/study/NCT05102019 IV Pulsed Field Ablation Still Looking Strong Management of OACs After PFA 10.1016/j.hrthm.2025.03.1952 External Link You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net